Persistent Activation of Chronic Inflammatory Pathways in Long Covid

Malika Aid,Katherine McMahan,Nicole Hachmann,Jessica Miller,Erica Borducchi,David Hope,Marjorie Rowe,Eleanor Schonberg,Siline Thai,Ai-ris Collier,Janet Mullington,Dan Barouch

DOI: https://doi.org/10.1101/2024.05.11.593709

2024-05-13

Abstract:Long Covid, or Post-Acute Sequelae of COVID-19 (PASC), involves a spectrum of chronic symptoms following resolution of acute SARS-CoV-2 infection. Current hypotheses for the pathogenesis of Long Covid include persistent SARS-CoV-2, activation of other viruses, tissue damage, autoimmunity, endocrine insufficiency, immune dysfunction, and complement activation. We evaluated 142 participants, including uninfected controls (N=35), acutely infected individuals (N=54), convalescent controls (N=25), and Long Covid patients (N=28), by comprehensive immunologic, virologic, transcriptomic, and proteomic analyses. Long Covid was characterized by persistent inflammatory pathways compared with convalescent controls and uninfected controls, including upregulation of IL-6 and JAK-STAT pathways as well as activation of coagulation, complement, metabolism, and T cell exhaustion pathways. Moreover, robust activation of these pathways during acute COVID-19 infection correlated with the subsequent development of Long Covid. In an independent validation cohort (N=47), Long Covid patients had higher levels of plasma IL-6R compared with convalescent controls and uninfected controls. These data demonstrate that Long Covid is characterized by persistent activation of chronic inflammatory pathways, suggesting novel therapeutic targets and biomarkers of disease.

Biology

What problem does this paper attempt to address?

The paper attempts to address the issue of **the pathological mechanisms of Long Covid**. Specifically, the researchers aim to explore the differences between Long Covid patients, recovered control group, and uninfected control group through comprehensive immunological, virological, transcriptomic, and proteomic analyses, thereby revealing the activation of persistent chronic inflammatory pathways in Long Covid patients. These findings help identify potential therapeutic targets and disease biomarkers.

### Main Research Questions:
1. **Pathological mechanisms of Long Covid**: Researchers hope to understand whether there is a persistent inflammatory response in Long Covid patients and the specific characteristics of this inflammatory response.
2. **Potential therapeutic targets**: By analyzing the immune and inflammatory responses of Long Covid patients, researchers hope to find new therapeutic targets to provide a basis for developing specific therapies for Long Covid.
3. **Disease biomarkers**: Researchers also aim to identify biomarkers that can be used for diagnosing and monitoring Long Covid for clinical application.

### Research Methods:
- **Participants**: The study includes 142 participants, divided into uninfected control group (N=35), acute infection group (N=54), recovered control group (N=25), and Long Covid patient group (N=28).
- **Analysis Methods**: Researchers used various analysis methods, including immunological testing, virological testing, transcriptome sequencing, and proteomic analysis, to comprehensively assess the immune and inflammatory status of the participants.

### Main Findings:
- **Persistent inflammatory response**: Long Covid patients exhibit persistent activation of inflammatory pathways, including upregulation of IL-6 and JAK-STAT pathways, and activation of coagulation, complement, metabolic, and T cell exhaustion pathways.
- **Early inflammatory markers**: During acute COVID-19 infection, activation of IL-6 and complement pathways is associated with the subsequent risk of developing Long Covid.
- **Validation study**: In an independent validation cohort, plasma IL-6R levels in Long Covid patients were significantly higher than in the recovered control group and uninfected control group.

These findings not only help to understand the pathological mechanisms of Long Covid but also provide potential therapeutic targets and biomarkers for future clinical trials.